NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Iodohippurate Sodium I-131 is a radioactive diagnostic agent used for renal imaging and function assessment via injection. It contains iodine-131, a beta-emitting radioisotope that allows visualization of kidney perfusion and tubular excretion. This agent helps clinicians evaluate renal blood flow, glomerular filtration, and urinary transport.
Pre-Launch
Pre-launch stage indicates limited current commercial infrastructure; teams will focus on regulatory pathway completion and market preparation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Iodohippurate Sodium I-131 offers early-career exposure to specialized nuclear medicine and diagnostic radiopharmaceutical development. The pre-launch stage provides opportunities to shape market strategy, regulatory pathways, and initial commercial infrastructure for a niche therapeutic area.
Regulatory Affairs SpecialistMedical Science Liaison
Worked on IODOHIPPURATE SODIUM I 131 at PharmaLundensis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.